Overview of Airpass
Airpass: Definition and Pharmacological Identity
| Property | Description |
|---|---|
| Active Ingredients | Levocetirizine, Montelukast |
| Form | Oral tablet, Oral granules (often film-coated) |
| Pharmacological Class | Antihistamine and Leukotriene Receptor Antagonist (LTRA) Combination |
| Origin | Synthetic chemical entities |
Airpass is defined as a fixed-dose combination product, integrating the two distinct, synthetic active ingredients, Levocetirizine and Montelukast, into a singular preparation. This medication is supplied as an oral dosage form, ensuring a systemic route of administration. Levocetirizine is the highly active R-enantiomer of cetirizine, and Montelukast is a selective anti-inflammatory agent. The benefit of this combined formulation is clinically recognized for offering a multifaceted treatment strategy that addresses complex allergic pathways simultaneously, synchronizing the delivery of the active components, which are typically used as Levocetirizine dihydrochloride and Montelukast sodium salts.
Dual Classification and Mechanism
The medication's identity is defined by its two primary mechanisms, classifying it as an Antihistamine and Leukotriene Receptor Antagonist (LTRA) Combination. The Levocetirizine component functions as a selective second-generation antihistamine, inhibiting the effects of histamine at the H1-receptor, which is crucial for controlling immediate allergic manifestations. Montelukast operates as a selective Leukotriene Receptor Antagonist that blocks the action of cysteinyl leukotrienes that drive inflammation and airway smooth muscle changes. These leukotriene antagonists help reduce swelling and airway tightening caused by allergic triggers. This dual pharmacological profile has become a standard strategy in addressing both chronic allergic rhinitis symptoms and underlying respiratory sensitivities.
General Purpose of the Combined Action
The general purpose of the combined formulation is to achieve a synergistic action that provides comprehensive control over the persistent symptoms and underlying inflammatory processes associated with allergic conditions. This dual therapeutic strategy is typically utilized in scenarios where histamine blockade alone proves insufficient. By combining the immediate action of the antihistamine with the sustained anti-inflammatory effect of the LTRA, the drug is designed to both alleviate acute allergic symptoms and mitigate the chronic inflammatory component, such as airway edema. This combination is highly valued because it targets two fundamental processes in allergic disease, offering a potentially broader spectrum of relief than a monotherapy.
Regulatory References
